Abstract
Introduction:
Incident frailty is common among older adults with diabetes mellitus. We have previously demonstrated that elevated serum levels of the soluble receptor for advanced glycation-end products (sRAGE) predict mortality in frail older adults. However, the evidence that sRAGE is associated with higher mortality in older adults with diabetes mellitus is rather inconsistent. Therefore, the aim of this study was to investigate whether frailty status influences the relationship between sRAGE and mortality in older adults with this diabetes mellitus.
Methods:
Three hundred and ninety-one participants with diabetes mellitus (median age, 76 years) from four European cohorts, who enrolled in the FRAILOMIC project were analysed. Frailty was evaluated at baseline using Fried’s frailty phenotype. Serum sRAGE was quantified by ELISA. Participants were stratified by frailty status (n = 280 non-frail and 111 frail). Multivariate Cox proportional hazards regression and Kaplan-Meier survival analysis were used to assess the relationship between sRAGE and mortality.
Results:
During 6 years of follow-up, 98 participants died (46 non-frail and 52 frail). Non-survivors had significantly higher baseline levels of sRAGE than survivors (median [IQR]: 1,392 [962–2,043] pg/mL vs. 1,212 [963–1,514], P = 0.008). High serum sRAGE (>1,617 pg/mL) was associated with increased mortality even after adjustment for relevant confounders (HR 2.06, 95% CI: 1.36–3.11, p < 0.001), and there was an interaction between sRAGE and frailty (P = 0.006). Furthermore, the association between sRAGE and mortality was stronger in the frail group compared to the non-frail group ((HR 2.52, 95% CI: 1.30–4.90, P = 0.006) vs. (HR 1.71, 95% CI: 0.91–3.23, P = 0.099, respectively)).
Conclusions:
Frailty status influences the relationship between sRAGE and mortality in older adults with diabetes mellitus. This has significant clinical potential in the risk stratification of diabetic patients.